Pediatr Nephrol (2011) 26:1937–1946 54. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S (2004) Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114(4):582–588 55. Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM, Hewison M (1999) Characterization of 11beta- hydroxysteroid dehydrogenase activity and corticosteroid recep- tor expression in human osteosarcoma cell lines. J Endocrinol 161:455–464 56. Eyre LJ, Rabbitt EH, Bland R, Hughes SV, Cooper MS, Sheppard MC, Stewart PM, Hewison M (2001) Expression of 11β-hydroxysteroid dehydrogenase in rat osteoblastic cells: pre- receptor regulation of glucocorticoid responses in bone. J Cell Biochem 81:453–462 57. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM (2000) Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 27:375–381 58. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM (2001) Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflamma- tory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16:1037–1044 59. Bowyer S, Roettcher P (1996) Pediatric rheumatology clinic populations in the United States: results of a 3-year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 23:1968–1974 60. Burnham JM, Shults J, Petit MA, Semeao E, Beck TJ, Zemel BS, Leonard MB (2007) Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease. J Bone Miner Res 22(4):551–559 61. Burnham JM, Shults J, Semeao E, Foster BJ, Zemel BS, Stallings VA, Leonard MB (2005) Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 82(2):413–420 62. Khadgawat R, Makharia GK, Puri K (2008) Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol 27 (3):103–106 63. Smith J, Lidofsky S (2009) Bone disease in the inflammatory bowel disease population. Med Health R I 92(4):125–127 64. Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB (2009) Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterol- ogy 136(1):123–130 65. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN, Reach Study Group (2008) Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 6(12):1378–1384 66. Tuchman S, Thayu M, Shults J, Zemel BS, Burnham JM, Leonard MB (2008) Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 153(4):484–490 67. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM (1998) Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 42:188–194 68. Silvennoinen J (1996) Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 239:131–137 1945 69. Varghese S, Wyzga N, Griffiths AM, Sylvester FA (2002) Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 35:641–648 70. Thayu M, Shults J, Burnham JM, Zemel BS, Baldassano RN, Leonard MB (2007) Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis 13(9):1121–1128 71. Sylvester FA, Davis PM, Wyzga N, Hyams JS, Lerer T (2006) Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr 148(4):461–466 72. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92(2):443–449 73. Weaver CM, Peacock M, Martin BR, McCabe GP, Zhao J, Smith DL, Wastney ME (1979) Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 12 (10):1714–1720 74. Blumsohn A, Hannon RA, Wrate R, Barton J, al-Dehaimi AW, Colwell A, Eastell R (1994) Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol 40(5):663–670 75. Rotteveel J, Schoute E, Delemarre-van de Waal HA (1997) Serum procollagen I carboxyterminal propeptide (PICP) levels through puberty: relation to height velocity and serum hormone levels. Acta Paediatr 86(2):143–147 76. Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S, Tanaka H, Seino Y (1997) Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 82 (7):2056–2061 77. Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M (2006) Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 8:R108 78. Bryndová J, Zbánková S, Kment M, Pácha J (2004) Colitis up- regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol 39:549–553 79. Stegk JP, Ebert B, Martin HJ, Maser E (2009) Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol 301:104–108 80. Czock D, Keller F, Rasche FM, Häussler U (2005) Pharmaco- kinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44(1):61–98 81. Taal MW, Masud T, Green D, Cassidy MJ (1999) Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Tranplant 14:1922–1928 82. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287–293 83. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Defini- tion, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953 84. Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Pediatric Dialysis Working Group (EPDWG) (2006) Prevention and